The global mycoplasma plate antigens market was valued at US$ 465 Million in 2021, and is projected to reflect a y-o-y growth rate of 6.5% in 2022 to reach US$ 495.35 Million in 2022. The market is expected to exhibit a CAGR of nearly 6% from 2022 to 2032, reaching US$ 880 Million by the end of the said forecast period.
| Report Attribute | Details |
|---|---|
| Expected Base Year Value (2021) | US$ 465 Million |
| Projected Market Value (2022) | US$ 495.32 Million |
| Anticipated Market Value (2032) | US$ 880 Million |
| Global Growth Rate (2022 to 2032) | 6% CAGR |
Mycoplasma plate antigens are used to detect antibodies against the etiologic agent of mycoplasma strains that cause chronic respiratory disease in chickens and infectious sinusitis in turkeys. Nasal discharge, coughing, airsacculitis, and respiratory rales are some of the most common symptoms of the disease.
Early detection of these diseases using commercially available mycoplasma plate antigens, kits, and reagents can help to avoid other negative consequences such as reduced feed conversion and egg production. As a result, it can help to mitigate the severe economic losses suffered by broiler and turkey production companies. The development of safe and effective vaccines directed against mycoplasma antigens is the best solution for controlling this disease.
Mycoplasma plate antigens are an effective tool for lowering the risk of disease transmission in the poultry bird population. As a result, flocks must be constantly monitored for Mycoplasma infections. Mycoplasma plate antigen detection tests that aid in screening for Mycoplasma and presenting disease status of individual birds. When used in a flock, the available reagents and kits on the market provide a simple method for detecting the presence of antibodies in the population.
Mycoplasma infection can occur in humans and other animals, usually as a result of close contact with infected poultry. In humans, these infections are associated with mild respiratory disease and can cause mild to severe illness. As a result, diagnosing mycoplasma plate antigens has become a common practice.
Many biochemical and physiological properties of some reagents and chemicals are usually insufficient for strain identification and classification based on the order mycoplasmatales. As a result, the serological properties of mycoplasma plate antigens are widely used for such purposes.
In comparison to other available reagents, these mycoplasma plate antigens provide more accurate quantification of antibodies against mycoplasma. These serological reactions are successfully used to identify antibodies against mycoplasma; however, research is still being conducted to determine the various cell components responsible for these reactions.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
China and India are expected to grow at a steady rate in the Asian mycoplasma plate antigens market over the forecast period. Factors such as a significant increase in import reforms for medical and life science products, as well as the presence of local manufacturers with R&D facilities in the region, are expected to drive the growth of the Mycoplasma Plate Antigens market in the region. Among other countries in the region, Japan, which has established R&D in medical devices as well as developed healthcare infrastructure, will contribute to the country's market growth for mycoplasma plate antigens.
Geographically, the global Mycoplasma Plate Antigens market is divided into the following key regions: North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa. In the forecasted period, North America is expected to account for one of the largest shares of the global mycoplasma plate antigens market. Increased drug development, infection medicine, veterinary research, and other cell-based studies are among the drivers for the region of North America.
Principal Consultant
Some of the key players present in global mycoplasma plate antigens market include Charles River, Prospec-Tany Technogene Lt, Abnova Corporation, Qiagen N.V, and MyBiosource, Inc. among others.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 6% until 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Product Type:
Application Type:
End User Type:
Region:
FMI projects the global Mycoplasma plate antigens market to expand at a 6% value CAGR by 2032.
Asia Pacific is expected to be the most opportunistic Mycoplasma plate antigens market.
Charles River, Prospec-Tany Technogene Ltd, Abnova Corporation, Qiagen N.V. and MyBiosource, Inc. are some prominent Mycoplasma plate antigens manufacturers.
Explore Healthcare Insights
View Reports
Mycoplasma Plate Antigens Market
